Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870520 | 0.82 | FLT3 (0.37) | MEN1KMT2AHTR6FLT3KDM4E | |
| SCHEMBL5716792 | 0.79 | PDGFRB (0.42) | MEN1KMT2AHTR6POLBL3MBTL1 | |
| SCHEMBL5716707 | 0.77 | KDM4E (0.41) | MEN1KMT2APDGFRBPDGFRAFLT3 | |
| SCHEMBL5716775 | 0.74 | KDM4E (0.39) | MEN1KMT2APDGFRBPDGFRAFLT3 | |
| 2-Methoxybenzaldehyde SCHEMBL7152818 | 0.73 | PDGFRB (0.36) | MEN1KMT2APOLBPDGFRBPDGFRA | |
| SCHEMBL6688305 | 0.72 | ALDH1A1 (0.42) | MEN1KMT2APOLBL3MBTL1PDGFRB | |
| SCHEMBL5716660 | 0.71 | KDM4E (0.39) | MEN1KMT2AFLT3KDM4EBCAT1 | |
| SCHEMBL6860277 | 0.69 | RECQL (0.58) | MEN1KMT2AHTR6POLBL3MBTL1 | |
| SCHEMBL6866893 | 0.69 | ALDH1A1 (0.58) | MEN1KMT2AHTR6POLBL3MBTL1 | |
| SCHEMBL20937286 | 0.68 | MEN1 (0.57) | MEN1KMT2AHTR6POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | MEN1 351/4885KMT2A 1101/4885HTR6 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.